entertainment -WSS

entertainment

author：leisure time 2025-10-01 21:35:35 - browse：2787

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Wikipedia

WSS

Mitch McConnell episode has important public health takeaway

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Key House panel plots a new health care package

FDA approves RSV monoclonal antibody for infants, toddlers

How dance can help nurses traumatized by Covid

Listen: Wegovy in the brain & pivotal Alzheimer's data

focus

entertainment

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

The high personal cost of affirmative action for Black doctors

After affirmative action ruling, medical educators look to 'holistic review'

The high personal cost of affirmative action for Black doctors

ChatGPT in medicine: STAT answers readers' burning questions

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Medical records are filled with copy

Sanofi seeks simpler, safer CRISPR sickle cell cure

Peter Hotez and the public health issue of online harassment

Sanofi seeks simpler, safer CRISPR sickle cell cure

entertainment

A public scorecard can help hold safety

Adults seen as increasingly susceptible to measles

Sage hopes for a blockbuster in antidepressant now before FDA

‘Oppenheimer’ and the risks of AI in health care

Micronoma's microbiome cancer diagnostic approach under fire

Key House panel plots a new health care package

Wikipedia

Wikipedia

Wikipedia

explore